Evidence map›Paper›PMID 37246974›Full record

ArticleAnnals of hematology2023

Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era.

Jelena Jelicic, Dennis Lund Hansen, Sarah Sand Carlsen, Michael Thorsgaard, Ditte Stampe Hersby, Karina Kannik, Amalie Sofie Eilsø Munksgaard, Thomas Stauffer Larsen, Karen Juul-Jensen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Jelena JelicicDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Dennis Lund HansenDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Sarah Sand CarlsenDepartment of Hematology, Zeeland University Hospital, Roskilde, Denmark.
Michael ThorsgaardDepartment of Hematology Vejle Hospital, Vejle, Denmark.
Ditte Stampe HersbyDepartment of Hematology, Copenhagen University Hospital, Rigshospitalet, Denmark.
Karina KannikDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Amalie Sofie Eilsø MunksgaardDepartment of Hematology, Zeeland University Hospital, Roskilde, Denmark.
Thomas Stauffer LarsenDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Karen Juul-JensenDepartment of Hematology, Odense University Hospital, Odense, Denmark. karen.juul-jensen@rsyd.dk.
Odense University Hospital · DKVejle Sygehus · DKAarhus University Hospital · DKRigshospitalet · DKUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, bone marrow (BM) biopsy (BMB) is recommended in the initial staging of patients with the presumed primary central nervous system (CNS) lymphoma (PCNSL). However, the added value of BMB in the era of positron emission tomography (PET-CT) has been challenged in other lymphoma subtypes. We analyzed BM findings in patients with biopsy-proven CNS lymphoma and a negative PET-CT scan for disease outside CNS. A comprehensive Danish population-based registry search was performed to identify all patients with CNS lymphoma of diffuse large B cell lymphoma (DLBCL) histology with available BMB results and staging PET-CT without systemic lymphoma. A total of 300 patients fulfilled the inclusion criteria. Of them, 16% had a previous history of lymphoma, while 84% were diagnosed with PCNSL. None of the patients had DLBCL in the BM. A minority (8.3%) had discordant BMB findings, mainly low-grade histologies that did not influence treatment choice in any case. In conclusion, the risk of overlooking concordant BM infiltration in patients with CNS lymphoma of DLBCL histology and negative PET-CT scan is negligible. As we did not find any patient with DLBCL in the BMB, our results suggest that BMB can be safely omitted in the diagnostic workup in patients with CNS lymphoma and a negative PET-CT.

Indexed as

Lymphoma, Large B-Cell, DiffusePositron Emission Tomography Computed TomographyBiopsyBone MarrowFluorodeoxyglucose F18HumansPositron-Emission TomographyRetrospective StudiesFluorodeoxyglucose F18Bone marrow biopsyCentral nervous system lymphomaDiffuse large B cell lymphomaPET-CT

Identifiers

PMID37246974
PMCPMC10261253
OpenAlexW4378640116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.